There is a dearth of population-based evidence regarding outcomes of the adolescent and young adult (AYA) population with gastrointestinal stromal tumors (GISTs).
ized by immunohistochemical staining for KIT protooncogene receptor tyrosine kinase (KIT) (OMIM 164920) (CD117). 3 In 2001, a GIST-specific histologic code was adopted, allowing for more accurate coding and reporting among national databases. [3] [4] [5] [6] Our group completed a contemporary analysis of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database since the adoption of this histologic code and found that the US incidence of GISTs is 6.8 cases per million persons. 7, 8 These tumors are most commonly located in the stomach followed by the small intestine and predominantly affect older patients and male patients, as well as black individuals and Asian/Pacific Islanders. [7] [8] [9] [10] [11] The molecular signature of GISTs has been more completely understood during the past 2 decades. 3 The 4 most common sporadic genetic alterations that lead to GISTs include gain-of-function mutations in KIT (c-KIT; 70%-80%), activating genomic alterations in platelet-derived growth factor receptor α (PDGFRA [ recently studied 95 patients with wild-type GISTs seen at the National Institutes of Health. These patients had a mean age of 23 years, and 88% were SDHB deficient, highlighting the unique nature of pediatric, adolescent, and young adult GISTs. The study of cancers among the adolescent and young adult (AYA) population has increased substantially during the past decades. [26] [27] [28] [29] [30] The definition of AYA varies but typically ranges from 13 to 40 years of age. This definition is based on differences between younger and older patients with regard to developmental and psychosocial needs, as well as genetic and pathologic differences in disease processes. 27, 28, [31] [32] [33] In addition, in many cancer types, survival is increasing at a slower rate within the AYA population compared with other age groups, highlighting the need for increased research on this vulnerable population. 29, 30, 34, 35 Currently, there is a dearth of knowledge regarding the outcomes of the AYA population with GISTs. Therefore, the aims of this study were to describe a large cohort of AYA patients with GISTs and to investigate the effect of operative management on overall survival (OS) and GISTspecific survival (GSS) using the National Cancer Institute's SEER database.
Methods
We identified patients in the SEER database diagnosed with GISTs from January Figure 1 . The institutional review board, overseen by the University of California, San Diego, Human Research Protections Program, deems studies of this nature exempt from review, so no informed consent was required. Demographic variables, including age at diagnosis, sex, and race, were extracted from SEER. We designated patients diagnosed with GIST at ages 13 to 39 years as AYA patients and those diagnosed at or after 40 years of age as older adult (OA) patients. In the United States, puberty usually occurs between the ages of 10 and 14 years in girls and between the ages of 12 and 16 years in boys. To focus primarily on postpubescent adolescent patients who are also distinct from prepubescent patients, we excluded the very small number of pediatric patients who were younger than 13 years old (n = 8 
Key Points
Question What is the association of operative management with overall and gastrointestinal stromal tumor-specific survival in adolescent and young adult patients with gastrointestinal stromal tumors?
Findings In this retrospective cohort study of 392 adolescent and young adult patients and 5373 older adult patients with histologically diagnosed gastrointestinal stromal tumors in the Surveillance, Epidemiology, and End Results database, the adolescent and young adult patients were more likely to undergo surgical management than the older adult patients.
Meaning Additional studies are needed to understand the long-term outcomes of adolescent and young adult patients with gastrointestinal stromal tumors and to further define the role of operative management among patients with metastatic disease in a more personalized manner.
cal variables and unpaired t tests for continuous variables. We excluded patients with multiple primary tumors from our analyses in the interest of accurately capturing GIST-specific mortality. Noncancer and cancer-specific deaths are explicitly captured in SEER; after limiting our cohort to include only those patients whose GIST was their first and only primary tumor, we were able to consider a cancer-related death as attributable to GIST. Survival time is defined as months from diagnosis to death or last known follow-up. We used competing risk analysis to investigate the effect of surgery on GIST-specific mortality, taking into account noncancer death as a competing event. We used multivariable Fine-Gray proportional hazards regression models to investigate the effect of surgery on GSS while adjusting for age at diagnosis, sex, race, year of diagnosis, geographic region, tumor site, summary stage, histologic grade, and mitotic index. Covariates for inclusion were defined a priori based on known and hypothesized confounders; however, histologic grade and mitotic index were removed from final models because of the large amount of missing data over concern for missing data bias. We performed subset analysis on AYA patients who presented with metastatic GISTs and used a cumulative incidence function to compare GSS between patients who did and did not undergo surgery, taking into account the competing risk of noncancer death. All data analysis was performed using SAS statistical software (SAS Institute Inc). Two-sided P < .05 was considered significant. 
Results

Cohort Characteristics
Surgical Management of AYA Patients
Of the 392 AYA patients with GISTs, 332 (84.7%) were managed operatively ( Table 2 
Survival Analysis
The 5-year GSS was 83.3% for AYA patients and 75.4% for OA patients (P < .001) (Figure 2A) . The 5-year OS was 82.4% for AYA patients and 67.1% for OA patients (P < .001), although this finding may be biased because of other comorbidities in the OA group (eFigure in the Supplement). In unadjusted analysis, 5-year GSS and OS were significantly higher in AYA patients who were managed operatively compared with those who were managed nonoperatively (GSS: 86.9% vs 64.3%, P < .001; OS: 86.1% vs 62.4%, P < .001) ( Figure 2B and eFigure in the Supplement).
On multivariable analysis of the 392 AYA patients, nonoperative management was associated with a 127% increased risk of GIST-specific death (subdistribution hazard ratio, 2.27; 95% CI, 1.21-2.25; P = .01) after adjusting for age, sex, race, year of diagnosis, and tumor size, site, and stage ( Table 3) . Male sex also increased the risk of death attributable to GISTs by 78% (subdistribution hazard ratio, 1.78; 95% CI, 1.04-3.04). Patients with regional or distant disease were at increased risk of GIST-specific death compared with patients with localized disease; similarly, patients with gastric tumors were at 
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increased risk of GIST-specific death compared with patients with small-intestine tumors (Table 3) . Given the finding that tumor location was associated with survival, we performed subset analysis of AYA patients with tumors of the small intestine (n = 139) or stomach (n = 210). There was improved GSS and OS among AYA patients with tumors of the small intestine compared with those with tumors of the stomach (GSS: 91.8% vs 78.0%, P = .008; OS: 91.1% vs 77.2%, P = .01) ( Figure 2C and eFigure in the Supplement).
Finally, given the lack of consensus on the management of many young patients with metastatic GISTs, we investigated the effect of resection in the subset of 91 AYA patients with metastatic disease. For these patients, the 5-year OS was 62.9% and the 5-year GSS was 65.3%. In stratified analysis, Copyright 2017 American Medical Association. All rights reserved.
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5-year GSS and OS were significantly higher in AYA patients with metastatic disease managed operatively compared with those managed nonoperatively (GSS: 71.5% vs 56.7%, P = .03; OS: 69.5% vs 53.7%, P = .04) ( Figure 2D and eFigure in the Supplement). Because of the limited number of patients who presented with distant disease, we were unable to perform multivariable analysis in this subset.
Discussion
This study provides the first statistical examination of a large cohort of AYA patients with GISTs since the adoption of precise immunohistochemical disease diagnosis in the United States. In general, the AYA cohort is an understudied population with unique characteristics, treatment responses, and psychosocial needs. Thus, we evaluated the characteristics of this cohort and investigated the effects of surgical intervention on patient survival, including among patients with metastatic disease. In our study, we found that AYA patients with GISTs have different characteristics than OA patients with GISTS, including a higher percentage of tumors in the small intestine and an increased likelihood of undergoing tumor resection. In addition, when evaluating AYA patients with metastatic disease, we found that there are significantly higher survival rates among patients selected for operative management compared with those selected for nonoperative management. Some specific characteristics of the AYA cohort are similar to those currently reported among all patients with GISTs. Adolescent and young adult patients have an equal distribution between the sexes and most frequently had localized disease in the stomach. 7 Among AYA patients, 23% presented with metastatic disease, which is comparable to previously reported rates among all patients with GISTs. 7, 37 In contrast to the OA cohort, AYA patients were more likely to be managed operatively irrespective of the stage of disease.
Limitations
When we investigated AYA patients with metastatic disease, we found that patients who were managed operatively had significantly higher GSS and OS compared with those who did not undergo surgery. There is potential for the introduction of Stratified by metastatic disease resection
A, GIST-specific survival stratified by age group. Also shown are GIST-specific survival of AYA patients stratified by resection (B), tumor site (C), and resection in the setting of metastatic disease (D).
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selection bias related to patients undergoing operative management. Because of the limited amount of information collected by cancer registrars (ie, presence or absence of distant disease), it is not possible to quantify tumor burden or describe patterns of metastatic disease (eg, lymph node, liver, or peritoneal based), which may have significant bearing on clinical decision making. Thus, although patients with a single metastasis and patients with a larger tumor burden beyond the primary site technically have distant disease, the former patients may be more likely to undergo resection compared with the latter. In the current study, it is not possible to specifically attribute improved outcomes to the operative management or a lower metastatic disease burden. Despite these limitations, these results support the concept that, in properly selected patients, the presence of resectable metastatic disease should not preclude young patients from undergoing surgical management because it is associated with improved survival end points. Our new findings complement prior studies 38,39 that have found that operative management is associated with improved survival in adult patients with metastatic GISTs. Numerous studies 40-42 evaluating adult patients with GISTs have reported that GISTs located in the small intestine have poorer outcomes than those located in the stomach. We now report a new and contradictory finding in AYA patients. In the current study, small-intestine location is associated with improved OS and GSS when compared with gastric location. The underlying mechanism for these differences may be attributable to differences in tumor biology (eg, genetic mutations). For example, NF1 mutant GISTs associated with neurofibromatosis type 1 most frequently occur in the small intestine, whereas SDHB-deficient GISTs (caused by SDHA, SDHB, SDHC, or SDHD mutations or SDHC epimutations) associated with CarneyStratakis syndrome most frequently occur in the stomach.
17,43
Further studies are necessary to elucidate the underlying biology or reasons leading to this unique finding among AYA patients compared with OA patients and current conventional wisdom in the GIST field. In addition to the aforementioned limitations, our study is confined to describing the AYA population of the SEER database; underreporting of GISTs has been found at the national cancer registry level because cancer registrars inappropriately code GISTs as benign. 44 However, this factor is unlikely to introduce systemic bias because this misreporting is likely relatively random and evenly distributed across the reporting sites. In recent years, SEER has captured mitotic index and tumor grade; however, we found that this field was often blank during the period studied. Thus, we were unable to control for high-risk tumor biology in our model. Over time with improved recording, these additional data will be valuable. Finally, the SEER registry only robustly captures the first course of any cancer-directed therapy. Without linking to a prospective data set (such as the Medicare claims data, which adds value only in patients 65 years and older), we do not have data regarding the role of adjuvant therapy in the AYA population.
Conclusions
To our knowledge, this study is the first population-based analysis of GIST outcomes in the AYA population. These patients are more likely to undergo surgical management than OA patients. Moreover, operative management was associated with improved OS and GSS in all AYA patients, including among those with metastatic disease. Further studies are needed to understand the long-term outcomes of AYA patients with GISTs and to determine the role of surgery among patients with metastatic disease in a more personalized manner. 
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